Cargando...
Impact of continued administration of tolvaptan on cirrhotic patients with ascites
BACKGROUND: The vasopressin V2-receptor antagonist tolvaptan is used to treat cirrhotic patients with ascites. We investigated the outcome of long-term treatment. METHODS: This was a single-center retrospective study. Overall, 170 cirrhotic patients (95 males, median age 63 years) were enrolled and...
Gardado en:
| Publicado en: | BMC Pharmacol Toxicol |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
BioMed Central
2018
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6299627/ https://ncbi.nlm.nih.gov/pubmed/30563565 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40360-018-0277-3 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|